Dual GIP/GLP-1 receptor agonist. CAS 2023788-19-2. 45mg/3ml vial, 135mg total API. Store 2-8°C.
Tirzepatide is a synthetic dual agonist of the GIP and GLP-1 receptors, studied for its combined effect on glucose-dependent insulinotropic signaling and appetite-regulating pathways. Its dual-receptor mechanism makes it a key reference compound in comparative incretin receptor research.
Every unit ships with a batch-specific Certificate of Analysis documenting purity, identity confirmation, appearance, and lot number.
Purity 98.8% · Identity confirmed
Third-party verification is available on request for wholesale and institutional buyers. Contact wholesale@marquepeptides.com.
Reconstitute with bacteriostatic water (BAC) at a concentration appropriate for your research protocol. Do not vortex; gently swirl until fully dissolved.
Handle in a clean laboratory environment. Use appropriate PPE (gloves, lab coat, eye protection). Refer to the MSDS included with your shipment for complete safety guidance.